A Comparison of Seroquel vs. Risperidone in Schizophrenia

This study has been completed.

Sponsor:

Information provided by:

AstraZeneca

ClinicalTrials.gov Identifier:

NCT00034905

First received: May 2, 2002

Last updated: January 3, 2013

Last verified: January 2013

History of Changes

Tracking Information
First Received Date ^ICMJE	May 2, 2002
Last Updated Date	January 3, 2013
Start Date ^ICMJE	July 2001
Primary Completion Date	September 2002 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT00034905 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	A Comparison of Seroquel vs. Risperidone in Schizophrenia
Official Title ^ICMJE	Not Provided
Brief Summary	The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 4
Study Design ^ICMJE	Primary Purpose: Treatment
Condition ^ICMJE	Schizophrenia
Intervention ^ICMJE	Drug: quetiapine fumarate vs risperidone
Study Arm (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	Not Provided
Completion Date	September 2002
Primary Completion Date	September 2002 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria Male / Female, 18-65 years old Schizophrenia (as per DSM IV) Exclusion Criteria Concurrent use of psychotropic medication Does not fulfill moderately ill on CGI
Gender	Both
Ages	18 Years to 65 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT Number ^ICMJE	NCT00034905
Other Study ID Numbers ^ICMJE	5077US/0043
Has Data Monitoring Committee	Not Provided
Responsible Party	Not Provided
Study Sponsor ^ICMJE	AstraZeneca
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	AstraZeneca
Verification Date	January 2013
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top